vimarsana.com

Latest Breaking News On - Largest series - Page 1 : vimarsana.com

Wa ed Ventures Leads a US $27 Million Series A Round for Rewaa, with Participation from STC s CIF, the Largest Series A Round for a SaaS Company in MENA

5 Dominating Speech AI Startups To Watch In 2023

Artificial intelligence (AI) companies now strive to innovate technologies that can interpret human language.

Takeaways From KTR Speech at TIE Global Summit 2022 Hyderabad

Given the volatile, uncertain, complex and ambiguous (VUCA) world we live in, innovation is a critical means by which countries can create and sustain competitive advantage and drive inclusive growth. Entrepreneurs create economic value and need to be motivated, cultivated and nurtured to the greatest degree. Webster’ Dictionary defines “ecosystem” as the complex of a

Weekly Startup Funding Roundup (November 07 to 11)

Quell Therapeutics Expands Series A Financing to $84 Million

Quell Therapeutics Expands Series A Financing to $84 Million Search jobs Quell Therapeutics Expands Series A Financing to $84 Million – Largest Series A in the Treg field –       London, UK – February 11 2021 – Quell Therapeutics Ltd (“Quell”), a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced the closing of an extended Series A financing led by their existing investors Syncona Ltd (“Syncona”), who have committed an additional $34.7 million and UCL Technology Fund (“UCLTF”) who have committed an additional $1 million; bringing the total Series A financing to circa $84 million.   Quell is funded to progress its program in liver transplantation to clinical proof of concept, whilst expanding its portfolio into autoimmune and neuroinflammatory diseases. Additionally, the funding will allow the Company to further develop scalable manufacturing processes and expand its senior leadership team.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.